Dumfries & Galloway Health Board
Prescribing Support Team

COPD Combination Inhaler Review

Posted: 20 May 15 Edited: 8 Aug 18
Audits Respiratory

Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled therapy is key to successful management of COPD. D&G formulary recommends either Duoresp® Spiromax® (a dry powder inhaler DPI) or Fostair® MDI as first line choice in patients, over 18 years of age, with COPD. Duoresp Spiromax® has been shown to have comparable quality and be bioequivalent to the same strengths of Symbicort® turbohaler. It is also expected to have the same benefits as Symbicort® in improving lung function and relieving symptoms in COPD